Roche Holding AG
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Bioavailability and Pharmacokinetic Study of Subcutaneous and Intravenous RO6811135 in Healthy Volunteers
- First Posted Date
- 2013-03-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT01802853
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
- First Posted Date
- 2013-02-28
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 138
- Registration Number
- NCT01801111
- Locations
- πΊπΈ
Rush University Medical Center, Chicago, Illinois, United States
πΊπΈUCLA Cancer Center; Premiere Oncology, A Medical Corporation, Santa Monica, California, United States
πΊπΈWashington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 282
- Registration Number
- NCT01798576
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues
- Conditions
- Hepatitis B, Chronic
- First Posted Date
- 2013-02-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT01794234
A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 223
- Registration Number
- NCT01793441
- Locations
- πΊπΈ
Neuroscientific Insights, Rockville, Maryland, United States
πΊπΈUniversity of California Davis, Sacramento, California, United States
πΊπΈMontefiore Medical Center; Departments of Psychiatry & Biobehavioral Science, Bronx, New York, United States
An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)
- Conditions
- Giant Cell Arteritis
- Interventions
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 251
- Registration Number
- NCT01791153
- Locations
- πΊπΈ
Univ of Calif., Los Angeles; Rheumatology, Los Angeles, California, United States
πΊπΈCedars-Sinai Medical Center, Los Angeles, California, United States
πΊπΈRheumatology Assoc. of S. Florida - Clinical Research Center, Boca Raton, Florida, United States
BEVERLY-C: An Observational Study of Avastin (Bevacizumab) in First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT01791140
ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 304
- Registration Number
- NCT01791205
An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT01790217
A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT01789788